Walleye Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$255K	Sell	26,793 -224,877	-89%	-$1.75M	﹤0.01%	3178
2025 Q4	$1.96M	Buy	251,670 +24,606	+11%	+$178K	0.01%	1889
2025 Q3	$1.72M	Sell	227,064 -2,073,564	-90%	-$17.3M	0.01%	1687
2025 Q2	$20.6M	Buy	2,300,628 +2,145,936	+1,387%	+$20M	0.19%	219
2025 Q1	$1.16M	Sell	154,692 -204,830	-57%	-$1.65M	0.01%	1852
2024 Q4	$2.7M	Buy	359,522 +100,140	+39%	+$760K	0.03%	1500
2024 Q3	$1.97M	Buy	259,382 +50,557	+24%	+$384K	0.02%	1966
2024 Q2	$1.29M	Buy	208,825 +145,073	+228%	+$801K	0.01%	2572
2024 Q1	$324K	Sell	63,752 -650,706	-91%	-$3.66M	﹤0.01%	3593
2023 Q4	$4.28M	Buy	714,458 +3,807	+0.5%	+$22.1K	0.06%	1205
2023 Q3	$5.03M	Buy	710,651 +534,472	+303%	+$3.84M	0.07%	1035
2023 Q2	$1.24M	Buy	176,179 +166,635	+1,746%	+$1.34M	0.02%	1667
2023 Q1	$79.6K	Sell	9,544 -595,989	-98%	-$5.74M	﹤0.01%	3042
2022 Q4	$6.95M	Buy	605,533 +364,119	+151%	+$4.54M	0.15%	197
2022 Q3	$3.04M	Buy	241,414 +181,816	+305%	+$2.34M	0.07%	362
2022 Q2	$631K	Sell	59,598 -122,969	-67%	-$1.27M	0.02%	904
2022 Q1	$2.97M	Buy	+182,567	New	+$2.93M	0.09%	258
2021 Q4	–	Sell	-41,131	Closed	-$591	–	2101
2021 Q3	$591	Buy	41,131 +27,173	+195%	+$429K	0.02%	715
2021 Q2	$221	Buy	+13,958	New	+$190K	0.01%	1037
2020 Q2	–	Sell	-156,507	Closed	-$313K	–	623
2020 Q1	$313K	Buy	156,507 +53,157	+51%	+$146K	0.1%	332
2019 Q4	$357K	Buy	+103,350	New	+$260K	0.08%	840